Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14179673 | 1.00 | CA2 (0.42) | CA2CA4MMEALDH1A1MEN1 | |
| SCHEMBL25761661 | 1.00 | CA2 (0.42) | CA2CA4MMEALDH1A1MEN1 | |
| SCHEMBL23142773 | 0.86 | MME (0.47) | CA2CA4MMEALDH1A1MEN1 | |
| SCHEMBL2916092 | 0.85 | CA2 (0.48) | CA2CA4MMETDP1FOLH1 | |
| SCHEMBL22019 | 0.85 | CA2 (0.48) | CA2CA4MMETDP1FOLH1 | |
| SCHEMBL2910640 | 0.85 | CA2 (0.48) | CA2CA4MMETDP1FOLH1 | |
| SCHEMBL1457564 | 0.85 | CA2 (0.48) | CA2CA4MMETDP1FOLH1 | |
| SCHEMBL13233705 | 0.84 | FNTA (0.35) | CA2CA4MMEALDH1A1TDP1 | |
| SCHEMBL21224515 | 0.84 | CA2 (0.41) | CA2CA4MMEALDH1A1TDP1 | |
| SCHEMBL20760840 | 0.84 | CA2 (0.41) | CA2CA4MMEALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2021-08-03 | — | — | US | disclosed |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | CA2 2750/4885CA4 2200/4885MME 4816/4885 |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | SI, SLC10A2, ALPI | CA2 2980/4885CA4 3581/4885MME 4718/4885 |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | CA2 2750/4885CA4 2200/4885MME 4816/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | CA2 2487/4885CA4 3091/4885MME 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.